A 144-week real-world outcomes of upadacitinib 30 mg for atopic dermatitis in poor responders to 15 mg

Supplementary Figure 1. Individual patient transitions of serum immunoglobulin E (IgE) and thymus and activation-regulated chemokine (TARC) at weeks 0, 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144 after dose increase of upadacitinib to 30 mg in patients with atopic dermatitis with insufficient response to 15 mg (n = 28). Each line represents one patient with available data (observed cases). Missing data were not imputed.

Supplementary Table 1. Baseline demographic and disease characteristics of patients with atopic dermatitis switched to upadacitinib 30 mg treatment from upadacitinib 15 mg (n = 28)

Supplementary Table 2. Treatment-emergent adverse events (TEAEs) during 144-week treatment of upadacitinib 30 mg in patients with atopic dermatitis switched from upadacitinib 15 mg (n = 28)